Transition Bio raised €47M in a Series A round in Jun 2022. The company is based in Cambridge, UK. Investors in the round: Bristol Myers Squibb, Lifeforce Capital, Magnetic Ventures and 2 others. Data as of 7 Aug 2026.
Confidence is the weaker of amount-FX and source evidence (the cascade rule). See methodology.
This is the company's only recorded round.
